BiotechTube

Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Coronary Artery Disease

Conditions

Coronary Artery Disease, Diabetes Mellitus Type 2

Trial Timeline

Feb 1, 2010 → Jul 1, 2014

NCT ID
NCT01021865

About Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere

Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere is a pre-clinical stage product being developed by Astellas Pharma for Coronary Artery Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01021865. Target conditions include Coronary Artery Disease, Diabetes Mellitus Type 2.

What happened to similar drugs?

20 of 20 similar drugs in Coronary Artery Disease were approved

Approved (20) Terminated (2) Active (0)
✅EvolocumabHeartFlowApproved
✅Clopidogrel treatment groupYuhanApproved
✅high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved
✅statins, ezetimibe + Combination therapyYuhanApproved
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
✅PrasugrelDaiichi SankyoApproved
✅Prasugrel + ClopidogrelDaiichi SankyoApproved

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01021865Pre-clinicalCompleted

Competing Products

20 competing products in Coronary Artery Disease

See all competitors
ProductCompanyStageHype Score
Rosuvastatin 40mg + PlaceboHeartFlowPre-clinical
27
EvolocumabHeartFlowApproved
29
High intensity lipid loweringHeartFlowPre-clinical
20
ExenatideEli LillyPhase 3
40
Clopidogrel treatment groupYuhanApproved
50
YH14659 + clopidogrel & aspirinYuhanPhase 1
29
high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved
43
Sarpogrelate + Aspirin + Clopidogrel + Placebo (for Sarpogrelate)YuhanPhase 3
40
statins, ezetimibe + Combination therapyYuhanApproved
50
YH14659 + clopidogrel & aspirinYuhanPhase 1
29
Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
43
clopidogrel + prasugrelDaiichi SankyoPhase 1
21
PrasugrelDaiichi SankyoApproved
43
ADP receptor inhibitorsDaiichi SankyoPre-clinical
26
Pactimibe, CS-505Daiichi SankyoPhase 2
35
Prasugrel + ClopidogrelDaiichi SankyoPhase 2
35
prasugrel + clopidogrelDaiichi SankyoPhase 1
29
Prasugrel + ClopidogrelDaiichi SankyoApproved
43
Triple oral lipid lowering treatmentDaiichi SankyoPhase 3
47
Placebo + PrasugrelDaiichi SankyoPhase 3
40